3 semaglutide Flex-Dose mL Injectable 2.5 mg/mL 1 receptor agonist). Semaglyn Injection (3 ml Cartridge
Description
PMID: 76 KimM

EU Revoked Patents on Oral Semaglutide EP2827845, covering a delivery agent composition for the tablet form (Rybelsus) EP2827885, related to GLP-1 peptide compositions

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

The dual mechanism may or may not carry different immunological implications than single-target GLP-1 agonists

Its reported side effects include headache, tachycardia, flushing, hypotension and urinary urgency

The multiple physiological effects of GLP1 make it a viable candidate for diabetes mellites and obesity therapies
